Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
July 2, 2018
PolarityTE Adds Peter Cohen, Former Board Member of the NYSE and Chairman and CEO of Cowen Inc., to the Board of Directors
SALT LAKE CITY, July 02, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (COOL) today announced that Peter Cohen will join PolarityTE’s Board of Directors. Mr. Cohen ...
July 2, 2018
Fortress Biotech Announces Cyprium Therapeutics’ CUTX-101 (Copper Histidinate) Granted FDA Fast Track Designation for Treatment of Classic Menkes Disease
NEW YORK, July 02, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and ...
June 29, 2018
Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients
LIVONIA, Mich., June 28, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
June 29, 2018
Sensorion Shows Protective Effect of SENS-401 in Hearing Loss Models
MONTPELLIER, France, June 29, 2018 (GLOBE NEWSWIRE) -- Sensorion(FR0012596468 – ALSEN), a biotech company specializing in the treatment of innerear diseases, presented data showing that ...
June 29, 2018
FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers
SAN DIEGO and TORONTO, June 29, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (APTO) (APS.TO) today announced that the U.S. Food and Drug Administration (FDA) ...
June 29, 2018
BioTime Awarded Grant From the NIH
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has been awarded a grant of $743,345 from ...
June 29, 2018
Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today will present preclinical and initial clinical data on ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) ...
June 29, 2018
AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency
NEW YORK, June 29, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies ...
June 28, 2018
AIT Therapeutics Announces Human and In-Vitro Nitric Oxide Data to be Presented at the 3rd Annual World Bronchiectasis Conference
NEW YORK, June 27, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide ...
June 28, 2018
BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello
NEW YORK and PETACH TIKVAH, Israel, June 28, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today ...
June 28, 2018
ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa
LEIDEN, the Netherlands, June 28, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA ...
June 28, 2018
Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease
CAMBRIDGE, Mass. & BOSTON--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (AKBA) and Keryx Biopharmaceuticals, Inc. (KERX) today announced that the companies signed, and the boards of directors of ...
June 28, 2018
InflaRx Receives IND Approval from the FDA to Start its Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis
JENA, Germany, June 28, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening inflammatory diseases by targeting the ...
June 28, 2018
RedHill Biopharma Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi®
TEL-AVIV, Israel and RALEIGH, N.C., June 28, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical ...
June 28, 2018
scPharmaceuticals Appoints Frederick Hudson to Board of Directors
BURLINGTON, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...
June 28, 2018
Entera Bio Ltd. Announces Pricing of Initial Public Offering
JERUSALEM, June 28, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (ENTX) (NASDAQ:ENTXW), a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered ...
June 27, 2018
Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on ...
June 27, 2018
Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
NEW YORK, June 27, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, ...
June 27, 2018
Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103
REHOVOT, Israel, and BRIDGEWATER, N.J., June 27, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and ...
June 27, 2018
Kitov to Host Business Update Conference Call on Monday, July 2
Tel Aviv, Israel, June 27, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (Nasdaq: KTOV; TASE: KTOV), an innovative biopharmaceutical company, today announced that it will ...
Page 29 of 117